NEOGENOMICS INC
NEONeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is an American CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. The company's testing services include cytogenetics, fluorescence in situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics.
Drugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
How NEO's past catalysts played out
No drugs found in this phase.
Frequently asked questions
When is NEOGENOMICS INC's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for NEOGENOMICS INC (NEO) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track NEO biotech catalysts?→
Add NEO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow NEOGENOMICS INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.